## Citation

Alison Brincat, Derek Stewart, Anita Weidmann, Patricia Vella Bonanno. Patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours: a systematic review. PROSPERO 2016 CRD42016048457 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42016048457

## Review question

The aim of the systematic review is to critically appraise, synthesise and present the available evidence of patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours.
In relation to the patients' pharmacological treatment journey for the management of malignant solid tumours:• What are the patients' lived experience?• What is the medication related burden? • What are the medication related beliefs?• What is the medication taking practice?• What is the relationship between the lived experience and medication related burden, medication related beliefs and medication taking practice?

## Searches

Systematic review according to PRISMA guidelines will be conducted in the following databases: CINAHL, MEDLINE, Cochrane Library, Embase, International pharmaceutical abstracts and PsycARTICLES. Manual searches of related studies listed in the reference, footnote and citations will be carried out to include more relevant papers. The search will be restricted to publications in the English language and will centre on the concepts of patients' lived experience, cytotoxic medications and malignant solid tumours. Concept mapping was applied to develop keywords and generate search terms.

## Types of study to be included

All study designs of research studies which have employed any methodological approach including quantitative or mixed methodologies will be included.

## Condition or domain being studied

The lived experiences of adult patients prescribed cytotoxic medications for the management of malignant solid tumours.

## Participants/population

Inclusion criteria: patients who are 18 years and over irrespective of their gender, ethnicity and stage of disease receiving cytotoxic medications for the management of malignant solid tumours.

## Intervention(s), exposure(s)

Articles will be reviewed if they describe the patients' lived experience of cytotoxic medications for the management of malignant solid tumours.

## Comparator(s)/control

Not applicable.

## Main outcome(s)

The primary outcomes will include the experiences, burden, beliefs and practice of patients in relation to cytotoxic medications.

## Additional outcome(s)

None.

## Data extraction (selection and coding)

The initial screening of all titles retrieved during the search will be carried out to identify potentially relevant papers. This will be followed by screening of abstracts and then by full paper against the pre-defined systematic review aim, questions and inclusion/exclusion criteria. A random sample of 10% of the retrieved titles and abstracts during the search strategy will be independently checked by two research members for

consistency of inclusion/exclusion and enhance the reliability of the process. Any disagreement will be resolved by consensus within the research team; otherwise these will be reported in the final review. Any duplicate publications of the same studies will be eliminated and the number of duplicates will be recorded using Prisma 2009 flow diagram.
Qualitative and quantitative data extraction will be conducted using standardised data extraction tools. These will be developed so as to obtain specific information pertinent to the review aim and questions.

## Risk of bias (quality) assessment
Quality assessment will be conducted on all included manuscripts by two independent reviewers using established critical appraisal tools. Disagreements will be resolved by consensus after discussion with the research team.

## Strategy for data synthesis
Research findings will be analysed using narrative and meta-synthesis approach.

## Analysis of subgroups or subsets
None planned

## Contact details for further information
Ms Brincat
a.brincat@rgu.ac.uk

## Organisational affiliation of the review
Robert Gordon University, Aberdeen Scotland

## Review team members and their organisational affiliations
Ms Alison Brincat. School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen Scotland
Professor Derek Stewart. School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen Scotland
Dr Anita Weidmann. School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen Scotland
Dr Patricia Vella Bonanno.

## Type and method of review
Systematic review

## Anticipated or actual start date
01 October 2016

## Anticipated completion date
28 February 2017

## Funding sources/sponsors
The project will be funded by the ‘Get Qualified Scheme’ upon successful completion of the doctorate course.

## Conflicts of interest
None known

## Language
English

## Country
Scotland

## Stage of review
Review Completed not published

## Subject index terms status
Subject indexing assigned by CRD

## Subject index terms
Antineoplastic Agents; Disease Management; Humans; Neoplasms

## Date of registration in PROSPERO
27 September 2016

## Date of first submission
30 July 2018

## Stage of review at time of this submission

| Stage | Started | Completed |
|---|---|---|
| Preliminary searches | Yes | Yes |
| Piloting of the study selection process | Yes | Yes |
| Formal screening of search results against eligibility criteria | Yes | Yes |
| Data extraction | Yes | Yes |
| Risk of bias (quality) assessment | Yes | Yes |
| Data analysis | Yes | Yes |

*The record owner confirms that the information they have supplied for this submission is accurate and complete and they understand that deliberate provision of inaccurate information or omission of data may be construed as scientific misconduct.*
*The record owner confirms that they will update the status of the review when it is completed and will add publication details in due course.*

## Versions
27 September 2016
08 August 2018